Equity, expense, and expertise in biologic commissioning: adding the patient to the equation

References

• Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18. doi: 10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465–479. doi: 10.1038/s41584-022-00798-0
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017 Jan;11(1):3–25. doi: 10.1093/ecco-jcc/jjw168
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017 Jul 1;11(7):769–784. doi: 10.1093/ecco-jcc/jjx009
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [Internet]. NG219: Crohn’s disease: management. Manchester (UK): NICE; 2019 [cited 2023 Sep]. Available from: https://www.nice.org.uk/guidance/ng129/chapter/Recommendations
   Google Scholar
• National Institute for Health and Care Excellence [Internet]. CG153: psoriasis: assessment and management. Manchester (UK): NICE; 2017 [cited 2023 Sep]. Available from: https://www.nice.org.uk/guidance/cg153/chapter/1-Recommendations
   Google Scholar
• National Institute for Health and Care Excellence [Internet]. NG130: ulcerative colitis: management. Manchester (UK): NICE; 2019 [cited 2023 Sep]. Available from: https://www.nice.org.uk/guidance/ng130/chapter/Recommendations
   Google Scholar
• NHS England [Internet]. Commissioning framework for biological medicines (including biosimilar medicines). Leeds (UK): NHS; 2017 [cited 2023 Oct]. Available from: https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf
   Google Scholar
• The King’s Fund [Internet]. The rising cost of medicines to the NHS – what’s the story? London (UK): The King’s Fund; 2018 [cited 2023 Aug]. Available from: https://assets.kingsfund.org.uk/f/256914/x/063e13bd4d/rising_cost_of_medicines_april_2018.pdf
   Google Scholar
• Alnahar S, Elliott RA, Smith MD. Biosimilar uptake by British local formularies: a cross sectional study. Int J Clin Pharm. 2017 Oct;39(5):1055–1060. doi: 10.1007/s11096-017-0523-6
   PubMed Web of Science ®Google Scholar
• NHS Confederation [Internet]. What were clinical commissioning groups? London (UK): NHS Confederation; 2021 [cited 2023 Oct]. Available from: https://www.nhsconfed.org/articles/what-are-clinical-commissioning-groups
   Google Scholar
• Checkland K, McDermott I, Coleman A, et al. Complexity in the new NHS: longitudinal case studies of CCGs in England. BMJ Open. 2016 Jan 7;6(1):e010199. doi: 10.1136/bmjopen-2015-010199
   PubMed Web of Science ®Google Scholar
• Mistry J, Hill D, Kaul A. P87 CCG biologics pathways: re-introduction of the postcode lottery by stealth. Rheumatology (Oxford). 2020 Apr;59(Supplement_2):87. doi: 10.1093/rheumatology/keaa111.085
   Google Scholar
• Wenzl M, McCuskee S, Mossialos E. Commissioning for equity in the NHS: rhetoric and practice. Br Med Bull. 2015 Sep;115(1):5–17. doi: 10.1093/bmb/ldv031
   PubMed Web of Science ®Google Scholar
• NHS [Internet]. ‘If I pay for private treatment, how will my NHS care be affected?’ Newcastle Upon Tyne (UK): NHS; 2022 [cited 2023 Sep]. Available from: https://www.nhs.uk/common-health-questions/nhs-services-and-treatments/if-i-pay-for-private-treatment-how-will-my-nhs-care-be-affected/
   Google Scholar
• NHS Bath and North East Somerset Swindon and Wiltshire Clinical Commissioning Group [Internet]. Moderate to severe plaque psoriasis biologic treatment pathway in adults. Chippenham (UK): Bath and North East Somerset, Swindon and Wiltshire Partnership; 2019 [cited 2023 Oct]. Available from: https://bswtogether.org.uk/medicines/wp-content/uploads/sites/3/2023/04/BSW-Plaque-Psoriasis-Pathway-April-2023.pdf
   Google Scholar
• Pan Mersey Area Prescribing Committee [Internet]. Psoriasis in adults, sequential use of biological agents. Leeds (UK): Pan Mersey Area Prescribing Committee; 2020 [cited 2023 Oct]. Available from: https://www.panmerseyapc.nhs.uk/media/2132/psoriasis_biologics.pdf
   Google Scholar
• Surrey and North West Sussex Area Prescribing Committee [internet]. Plaque psoriasis drug treatment pathway. Surrey, (UK): Surrey and North West Sussex Area Prescribing Committee; 2019 [cited 2023 Sep]. Available from: https://surreyccg.res-systems.net/PAD//Content/Documents/2/FINAL%20Psoriasis%20treatment%20pathway%20september%202019.pdf
   Google Scholar
• Raine T, Gkini MA, Irving PM, et al. Maintaining clinical freedom whilst achieving value in biologics prescribing: an integrated cross-specialty consensus of UK dermatologists, rheumatologists and gastroenterologists. BioDrugs. 2021 Mar;35(2):187–199. doi: 10.1007/s40259-020-00464-5
   PubMed Web of Science ®Google Scholar
• Kaul A, Mistry J, Iagnocco A, et al. Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery? Rheumatol Adv Pract. 2021 Nov;5(3):rkab081. doi: 10.1093/rap/rkab081
   PubMedGoogle Scholar
• NHS England [Internet]. What are integrated care systems? Leeds (UK): NHS; 2022 [cited 2023 Oct]. Available from: https://www.england.nhs.uk/integratedcare/what-is-integrated-care/
   Google Scholar
• Coyle C, Watson L, Whately-Smith C, et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 [cited 2024 Jan 8]. doi: 10.1093/rheumatology/kead679
   PubMed Web of Science ®Google Scholar
• Watson L, Coyle C, Whately-Smith C, et al. An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. Rheumatology (Oxford). 2023 [cited 2023 Nov 27]. doi: 10.1093/rheumatology/kead621
   Web of Science ®Google Scholar
• Nutbeam D, Lloyd JE. Understanding and responding to health literacy as a social determinant of health. Annu Rev Public Health. 2021 Apr 1;42(1):159–173. doi: 10.1146/annurev-publhealth-090419-102529
   PubMedGoogle Scholar
• Liu C, Wang D, Liu C, et al. What is the meaning of health literacy? A systematic review and qualitative synthesis. Fam Med Community Health. 2020 May;8(2):e000351.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [Internet]. ECD8: standards framework for shared-decision-making support tools, including patient decision aids. Manchester (UK): NICE; 2021 [cited 2023 Sep]. Available from: https://www.nice.org.uk/corporate/ecd8
   Google Scholar
• Martinez B, Dailey F, Almario CV, et al. Patient understanding of the risks and benefits of biologic therapies in inflammatory bowel disease: insights from a large-scale analysis of social media platforms. Inflamm Bowel Dis. 2017 Jul;23(7):1057–1064. doi: 10.1097/MIB.0000000000001110
   PubMed Web of Science ®Google Scholar
• National Axial Spondyloarthritis Society [Internet]. What do patients value and need in the diagnosis, treatment and care of axial spondyloarthritis? London (UK): NASS; 2022 [cited 2023 Sep]. Available from: https://nass.co.uk/wp-content/uploads/2022/11/NAS-Patient-Values-Report-DIGITAL.pdf
   Google Scholar
• NHS: Health Education England [Internet]. Improving health literacy - better health through improved health literacy. Leeds (UK): NHS; [cited 2023 Oct]. Available from: https://www.hee.nhs.uk/our-work/knowledge-library-services/improving-health-literacy
   Google Scholar
• National Institute for Health and Care Excellence [Internet]. NG197: shared decision making. Manchester (UK): NICE; 2021 [cited 2023 Sep]. Available from: https://www.nice.org.uk/guidance/ng197
   Google Scholar
• Murray S, Augustyniak M, Murase JE, et al. Barriers to shared decision-making with women of reproductive age affected by a chronic inflammatory disease: a mixed-methods needs assessment of dermatologists and rheumatologists. BMJ Open. 2021 Jun 16;11(6):e043960. doi: 10.1136/bmjopen-2020-043960
   PubMed Web of Science ®Google Scholar
• Zisman-Ilani Y, Thompson KD, Siegel LS, et al. Crohn’s disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 Jan;57(2):205–214. doi: 10.1111/apt.17286
   PubMed Web of Science ®Google Scholar
• Tierney S, Wong G, Mahtani KR. Current understanding and implementation of ‘care navigation’ across England: a cross-sectional study of NHS clinical commissioning groups. Br J Gen Pract. 2019 Oct;69(687):e675–e681. doi: 10.3399/bjgp19X705569
   PubMed Web of Science ®Google Scholar
• Taylor PC, Betteridge N, Brown TM, et al. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020 Jan 20;14:119–131. doi: 10.2147/PPA.S220714
   PubMed Web of Science ®Google Scholar
• IBDrelief [Internet]. Impact of IBD on physical and emotional health: findings from an IBDrelief survey. Shoreham-by-Sea. (UK): IBD Relief Ltd; 2022 [cited 2023 Oct]. Available from: https://www.ibdrelief.com/ibd-medication-adherence-survey-report
   Google Scholar
• Rubin DT, Sninsky C, Siegmund B, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflamm Bowel Dis. 2021 Nov 15;27(12):1942–1953. doi: 10.1093/ibd/izab006
   PubMed Web of Science ®Google Scholar
• The Patients’ Association [Internet]. Understanding patient needs in switching from biologic to biosimilar medicines: final report of survey and focus group findings. San Francisco (CA): WordPress; 2018 [cited 2023 Oct]. Available from: https://allcatsrgrey.org.uk/wp/download/pharmacy/Understanding_patient_needs_in_switching_from_biologic_to_biosimilar_medicines.pdf
   Google Scholar
• Kumar K, Raizada SR, Mallen CD, et al. UK-South Asian patients’ experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis. Patient Prefer Adherence. 2018 Apr 4;12:489–497. doi: 10.2147/PPA.S153741
   PubMed Web of Science ®Google Scholar
• Faraoni D, Schaefer ST. Randomized controlled trials vs. observational studies: why not just live together? BMC Anesthesiol. 2016 Oct 21;16(1):102. doi: 10.1186/s12871-016-0265-3
   PubMedGoogle Scholar
• Pearce W, Raman S, Turner A. Randomised trials in context: practical problems and social aspects of evidence-based medicine and policy. Trials. 2015 Sep 1;16(1):394. doi: 10.1186/s13063-015-0917-5
   PubMedGoogle Scholar
• Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG. 2018 Dec;125(13):1716. doi: 10.1111/1471-0528.15199
   PubMed Web of Science ®Google Scholar
• Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021 Jul;12(3):171–174. doi: 10.4103/picr.picr_62_21
   PubMedGoogle Scholar
• Patel A. Getting It Right First Time (GIRFT) – dermatology. A clear path to clear skin: a pharmacist’s perspective. J Med Optim. 2021;7(2):54–59.
   Google Scholar
• Barker JB. Biosimilars. J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1054. doi: 10.1111/jdv.15066
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Biosimilars: review and approval. White Oak, MD (US); 2022. [cited 2024 Mar]. Available from: https://www.fda.gov/drugs/biosimilars/review-and-approval
   Google Scholar
• Gecse KB, Cumming F, D’Haens G. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients’ concerns? Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):143–155. doi: 10.1080/17474124.2019.1553617
   PubMed Web of Science ®Google Scholar
• Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019 May;180(5):1069–1076. doi: 10.1111/bjd.16776
   PubMed Web of Science ®Google Scholar
• Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017 Jun;19(6):37. doi: 10.1007/s11926-017-0658-4
   PubMed Web of Science ®Google Scholar
• Allocati E, Godman B, Gobbi M, et al. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022 Aug;13:917814. doi: 10.3389/fphar.2022.917814
   PubMed Web of Science ®Google Scholar
• The King’s Fund [Internet]. Integrated care systems explained: making sense of systems, places, and neighbourhoods. London (UK): The King’s Fund; 2022 [cited 2023 Oct]. Available from: https://www.kingsfund.org.uk/publications/integrated-care-systems-explained
   Google Scholar
• Lewis RQ, Checkland K, Durand MA, et al. Integrated care in England - what can we learn from a decade of national pilot programmes? Int J Integr Care. 2021 Oct;21(4):5.doi: 10.5334/ijic.5631
   PubMedGoogle Scholar
• Coultas C, Kieslich K, Littlejohns P. Patient and public involvement in priority-setting decisions in England’s transforming NHS: an interview study with clinical commissioning groups in South London sustainability transformation partnerships. Health Expect. 2019 Dec;22(6):1223–1230. doi: 10.1111/hex.12948
   PubMed Web of Science ®Google Scholar
• Smiddy J, Reay J, Peckham S, et al. Developing patient reference groups within general practice: a mixed-methods study. Br J Gen Pract. 2015 Mar;65(632):e177–83. doi: 10.3399/bjgp15X683989
   PubMed Web of Science ®Google Scholar
• Liu E, Jatale R, DeSilva D, et al. PMO-39 Factors influencing delays in biologic initiation in inflammatory bowel disease. Gut. 2021;70(Suppl 4):A96–A97.
   Google Scholar
• Romao VC, Vital EM, Fonseca JE, et al. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3
   PubMedGoogle Scholar
• Goyal DK, Mansab F, Naasan AP, et al. Restricted access to the NHS during the COVID-19 pandemic: is it time to move away from the rationed clinical response? Lancet Reg Health Eur. 2021 Sep;8:100201. doi: 10.1016/j.lanepe.2021.100201
   PubMedGoogle Scholar
• Majeed A, Maile EJ, Bindman AB. The primary care response to COVID-19 in England’s National Health Service. J R Soc Med. 2020 Jun;113(6):208–210. doi: 10.1177/0141076820931452
   PubMed Web of Science ®Google Scholar
• Patient Experience Platform Health [internet]. What Patients Think 2: trends and variation in patient experience across hospital trusts in England 2020-21. London (UK): Statica Research Ltd; 2021 [cited 2023 Sep]. Available from: https://www.pephealth.ai/what-patients-think-2021.
   Google Scholar
• Marzorati C, Pravettoni G. Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes. J Multidiscip Healthc. 2017 Mar;10:101–106. doi: 10.2147/JMDH.S122383
   PubMed Web of Science ®Google Scholar
• Moots RJ, Curiale C, Petersel D, et al. Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review. BioDrugs. 2018 Jun;32(3):193–199. doi: 10.1007/s40259-018-0283-4
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. PharmacoEconomics. 2014 Jul;32(7):681–691. doi: 10.1007/s40273-014-0163-9
   PubMed Web of Science ®Google Scholar
• Garrison L Jr., Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017 Feb;20(2):213–216. doi: 10.1016/j.jval.2016.12.005
   PubMed Web of Science ®Google Scholar
• Rencz F, Poor AK, Pentek M, et al. A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2018 May;32(5):783–790. doi: 10.1111/jdv.14676
   PubMed Web of Science ®Google Scholar
• Poor AK, Brodszky V, Pentek M, et al. Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch Dermatol Res. 2018 Jan;310(1):47–55. doi: 10.1007/s00403-017-1794-4
   PubMed Web of Science ®Google Scholar
• Public Health England [Internet]. Improving health literacy to reduce health inequalities: practice resource summary. London (UK): Public Health England; 2015 [cited 2023 Oct]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/460710/4b_Health_Literacy-Briefing.pdf
   Google Scholar
• NHS England [Internet]. Dermatology GIRFT programme national specialty report. Leeds (UK): NHS; 2021 [cited 2023 Oct]. Available from: https://gettingitrightfirsttime.co.uk/wp-content/uploads/2021/09/DermatologyReport-Sept21o.pdf
   Google Scholar